DGX
Quest Diagnostics Incorporated
DGX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over DGX overall, supported by stronger valuation and stronger fundamentals.
DGX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Stable |
DGX's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DGX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $102 | -61% |
| Fair | 19x | $192 | -26% |
| Expensive | 22x | $220 | -15% |
| Forward | 22x | $260 | — |
| Current | 26x | $260 | — |
Historical ranges are pointers, not guarantees.
DGX's PE is in its expensive range at 26x. If earnings grow as analysts expect, today's price would be 22x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over DGX in the historical PE scenario, which offers more potential upside but is not a forecast.
DGX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for DGX, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over DGX on the outlook, with more favorable profitability expectations.
DGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.60 | +16% |
| Q3 2026 | $10.04 | +18% |
| Q2 2026 | $9.42 | +13% |
| Q1 2026 | $9.05 | +14% |
| Q4 2025 | $8.75 | +14% |
| Q3 2025 | $8.52 | +15% |
| Q2 2025 | $8.35 | +13% |
| Q1 2025 | $7.91 | +6.5% |
| Q4 2024 | $7.69 | +2.7% |
DGX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
DGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.1B | +10% |
| Q2 2026 | $3B | +10% |
| Q1 2026 | $2.9B | +9.2% |
| Q4 2025 | $2.8B | +7.1% |
| Q3 2025 | $2.8B | +13% |
| Q2 2025 | $2.8B | +15% |
| Q1 2025 | $2.7B | +12% |
| Q4 2024 | $2.6B | +15% |
DGX's revenue has grown year over year for 11 quarters in a row: $3.1B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.8 points |
| Q2 2026 | 15% | -0.8 points |
| Q1 2026 | 14% | +0.7 points |
| Q4 2025 | 14% | 0 points |
| Q3 2025 | 14% | +0.5 points |
| Q2 2025 | 16% | +1 points |
| Q1 2025 | 13% | +0.4 points |
| Q4 2024 | 14% | +2.1 points |
DGX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over DGX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
DGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $445M | +6.2% |
| Q2 2026 | $459M | +5.3% |
| Q1 2026 | $164M | -17% |
| Q4 2025 | $307M | -10% |
| Q3 2025 | $419M | +68% |
| Q2 2025 | $436M | +63% |
| Q1 2025 | $197M | +294% |
| Q4 2024 | $341M | -25% |
DGX still generates free cash flow, though less than at its 2020 peak: $1.4B over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over DGX on cash flow, with more consistent year-over-year improvement.
DGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -0.9% | -1M shares |
| 3 years | -1.8% | -2M shares |
| 5 years | -10% | -13M shares |
| Available history | -18% | -24M shares |
DGX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $150M |
| Q4 2025 | $300M |
| Q4 2023 | $275M |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $461M |
| Q3 2022 | $374M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DGX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 2.5x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.0x | Moderate |
| Q4 2024 | 3.1x | Elevated |
DGX's net debt is about 2.1 years of its operating earnings (EBITDA), down from 2.5 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over DGX on leverage, with a lower net debt burden relative to earnings.
DGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.0 | Neutral |
| Stochastic | 89.7 | Overbought |
DGX's weekly RSI is 70 (neutral) and its Stochastic is 90 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DGX PE vs Healthcare Sector
| Metric | DGX | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | Same PE |
| PE % | 99 | 29 | 70 pts above |
DGX is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over DGX on valuation relative to its sector.
DGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $243.1 | 6.8% above |
| 20 week MA | $235.9 | 10% above |
| 50 week MA | $209.8 | 24% above |
| 100 week MA | $191.5 | 36% above |
| 200 week MA | $165.4 | 57% above |
DGX is in an uptrend: it's above all five of its weekly moving averages, and 57% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
DGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $106.9 | $120.2 | +13% |
| 2021 | $120.2 | $167.1 | +39% |
| 2022 | $167.1 | $156.3 | -6.4% |
| 2023 | $156.3 | $137.9 | -12% |
| 2024 | $137.9 | $152.6 | +11% |
| 2025 | $152.6 | $175.9 | +15% |
| 2026 YTD | $175.9 | $259.7 | +48% |
DGX has finished higher in four of the last six years. It's up 48% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DGX on returns for 2026, with the stronger performance.